Abstract Details

Title Common γ-chain blocking peptide reduces in vitro immune activation markers in HTLV-1 associated myelopathy/ tropical spastic paraparesis.

Topic Global Health and Neuroepidemiology

Presentation(s) (-)

Poster/Presentation
Number 299

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Raya Massoud, MD (Progressive Neurology LLC) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Steven Jacobson (NIH)	Steven Jacobson has nothing to disclose.
Joseph F. Quinn, MD, FAAN (OHSU Neurology)	Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Retrophin. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Disease Cooperative Study. Dr. Quinn has received personal compensation in the range of $500-$4,999 for serving as a DSMB with Alzheimer's Therapeutic Research Institute. Dr. Quinn has a non-compensated relationship as a consultant with Cognition Therapeutics that is relevant to AAN interests or activities.

��ɫ��